Cargando…

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin

PURPOSE: Chemotherapy treatment in premenopausal women has been linked to ovarian follicle loss and premature ovarian failure; the exact mechanism by which this occurs is uncertain. Here, two commonly used chemotherapeutic agents (cisplatin and doxorubicin) were added to a mouse ovary culture system...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Stephanie, Lopes, Federica, Gourley, Charlie, Anderson, Richard A., Spears, Norah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726485/ https://www.ncbi.nlm.nih.gov/pubmed/23922929 http://dx.doi.org/10.1371/journal.pone.0070117

Ejemplares similares

Single and combined effects of cisplatin and doxorubicin on the human and mouse ovary in vitro
por: Lopes, Federica, et al.
Publicado: (2019)

Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis
por: Smart, Ellie, et al.
Publicado: (2018)

Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles
por: Lopes, Federica, et al.
Publicado: (2014)

Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads
por: Allen, Caroline M, et al.
Publicado: (2020)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Culture and Co-Culture of Mouse Ovaries and Ovarian Follicles
por: Morgan, Stephanie, et al.
Publicado: (2015)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

Cisplatin Effects on the Human Fetal Testis – Establishing the Sensitive Period for (Pre)Spermatogonial Loss and Relevance for Fertility Preservation in Pre-Pubertal Boys
por: Matilionyte, Gabriele, et al.
Publicado: (2022)

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
por: Tempfer, Clemens B., et al.
Publicado: (2017)

The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer
por: Chitcholtan, Kenny, et al.
Publicado: (2012)

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
por: Sherman-Baust, Cheryl A, et al.
Publicado: (2011)

Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
por: Gorodnova, Tatiana V., et al.
Publicado: (2021)

Cisplatin/dexrazoxane/doxorubicin: Neutropenia and thrombocytopenia: case report
Publicado: (2020)

Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries
por: Marcozzi, Serena, et al.
Publicado: (2019)

Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006)

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Cisplatin and carboplatin result in similar gonadotoxicity in immature human testis with implications for fertility preservation in childhood cancer
por: Tharmalingam, Melissa D., et al.
Publicado: (2020)

Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
por: Grabosch, Shannon, et al.
Publicado: (2018)

Cisplatin induces stemness in ovarian cancer
por: Wiechert, Andrew, et al.
Publicado: (2016)

Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
por: Sharp, S. Y., et al.
Publicado: (1994)

Oocyte CTR1 is not essential for cisplatin-induced oocyte death of primordial follicle
por: Yu, Seok-Yeong, et al.
Publicado: (2022)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Sulforaphane Potentiates Anticancer Effects of Doxorubicin and Cisplatin and Mitigates Their Toxic Effects
por: Calcabrini, Cinzia, et al.
Publicado: (2020)

Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
por: Mayr, Martina, et al.
Publicado: (2012)

lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer
por: Li, Qing, et al.
Publicado: (2018)

Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells
por: Chun, Jaemoo
Publicado: (2023)

Impact of imatinib administration on the mouse ovarian follicle count and levels of intra-ovarian proteins related to follicular quality
por: Kim, Se Jeong, et al.
Publicado: (2022)

Cisplatin Induces Overactivation of the Dormant Primordial Follicle through PTEN/AKT/FOXO3a Pathway which Leads to Loss of Ovarian Reserve in Mice
por: Chang, Eun Mi, et al.
Publicado: (2015)

Cisplatin/carboplatin cross-resistance in ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1989)

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer
por: XIE, YA, et al.
Publicado: (2014)

Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low‐dose fraction radiation
por: Zhao, Lili, et al.
Publicado: (2019)

Apoptosis Induction with Combined Use of Cisplatin and Fisetin in Cisplatin-Resistant Ovarian Cancer Cells (A2780)
por: Jafarzadeh, Samira, et al.
Publicado: (2021)

Potentiation of Cisplatin Cytotoxicity in Resistant Ovarian Cancer SKOV3/Cisplatin Cells by Quercetin Pre-Treatment
por: Hasan, Aseel Ali, et al.
Publicado: (2023)

Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
por: Ma, Ming-Chun, et al.
Publicado: (2014)

Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma: Two case reports
por: Lewcun, Joseph A., et al.
Publicado: (2020)

Palmitate Enhances the Efficacy of Cisplatin and Doxorubicin against Human Endometrial Carcinoma Cells
por: Wu, Zih-Syuan, et al.
Publicado: (2021)

Self-Reporting Polysaccharide Polymersome for Doxorubicin and Cisplatin Delivery to Live Cancer Cells
por: Virmani, Mishika, et al.
Publicado: (2021)

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
por: Hollis, Robert L, et al.
Publicado: (2017)

Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
por: Huang, Wei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5pt7k2pm89vjomf0cab8r08rf4